Latest "Vivos Therapeutics" News Stories

00:22 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Vivos Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Vivos Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Vivos Therapeutics for you to read. Along with our medical data and news we also list Vivos Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Vivos Therapeutics Companies for you to search.

Showing "Vivos Therapeutics" News Articles 1–25 of 8,200+

Monday 18th February 2019

2019: CRISPR and therapeutic gene editing comes of age

Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?

The Global Pain Therapeutics Market Outlook to 2023 – Anticipated Arrival of Abuse-Deterrent Opioids and Monoclonal Antibodies should Help Revitalize the Market for Pain Therapies –

DUBLIN–(BUSINESS WIRE)–The “The Global Pain Therapeutics Market, 6th Edition: Market Trends & R&D Insights” report has been added to’s offering. In 2018, the leading branded pain therapeutics market will generate a massive $26.3 billion, down 30.3% from 2017 total … Continue reading →

A Report from the Longevity Therapeutics Summit

This was the first year for the Longevity Therapeutics Summit in San Francisco, California. Ably organized by Hanson Wade, with John Lewis, CEO of Oisín Biotechnologies, as program chair, the conference focused on senolytics for senescent cell clearance, big data and AI in finding new drugs (“in silico” testing), delivery systems for therapeutics like senolytics,...

Arvelle Therapeutics raises $180m in Series A financing

Enormous Series A to Help Bring Epilepsy Drug to Market

One of the biggest Series A rounds in European biotech, €159M ($180M), has been raised by the Swiss company Arvelle Therapeutics to help commercialize its epilepsy drug. Formed just this month, Arvelle plans to submit an application for EMA approval for the small molecule drug cenobamate, which it has licensed from the South Korean company […] The post Enormous Series A to Help Bring Epile...

Exicure to Present at SMi’s RNA Therapeutics 2019 Conference

Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present at SMi’s RNA Therapeutics 2019 Conference being held February 20-21, 2019 at the Copthorne Tara Hotel in London, UK. Dr. Giljohann’s presentation tit...

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps...   

Troubled Realm Therapeutics Selling Assets, Delisting From London AIM

US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.   

Pipeline Watch: Phase III Starts In Prostate Cancer, C Diff Diarrhea

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...   

CymaBay gets FDA breakthrough status for seladelpar

CymaBay Therapeutics' seladelpar, being developed to treat adult patients with early-stage primary biliary cholangitis, has b -More- 

Australia Tries Again At Tightening Personalized And 3D-Printed Device Rules

The Therapeutics Goods Administration has begun a second public consultation on how it intends to improve its rules for 3D-printed...    

New Early Breast Cancer Drug To Be Made Available In Singapore Via Special Access Program

- Specialised Therapeutics Asia to make NERLYNX® (neratinib) available to women in Singapore - Five-year follow up data shows NERLYNX reduces risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer[1] - Subsidised Singapore Special Access Program open today to patients with HER2-overexpressing cancers ...

Sunday 17th February 2019

Global Hematological Malignancies Disease Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryThe global Hematological Malignancies Disease market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Major ApplicationMajor TypeKey manufacturers are included ...

Denali starts DNL747 dosing in Phase Ib Alzheimer’s trial

US-based biopharmaceutical firm Denali Therapeutics has started dosing patients with its investigational drug DNL747 in a Phase Ib clinical trial...Read More... The post Denali starts DNL747 dosing in Phase Ib Alzheimer’s trial appeared first on Drug Development Technology.

Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

CAMBRIDGE, Mass., Feb. 18, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced plans to host its fourth quarter and full year 2018 financial results and corporate highlights conference call and live webcast on Tuesday, February 26, 2019 at 4:30 ...

5 Top Weekly NASDAQ Biotech Stocks: Index in the Green Again

Melinta Therapeutics, BioXcel Therapeutics, Eyenovia, Forward Pharma and Trevena were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Index in the Green Again appeared first on Investing News Network.

Saturday 16th February 2019

Week in Review: CStone's Hong Kong IPO to Raise $304 Million at $1.5 Billion Valuation Next Week

Deals and Financings • CStone Pharma of Suzhou will raise $304 million next week in its Hong Kong IPO at a valuation of $1.5 billion to advance fourteen clinical-stage oncology candidates;• Shanghai HaiHe Biopharma, an oncology company with ten molecules in clinical trials, announced a $146.6 million funding;• Burning Rock Biotech, a Guangzhou diagnostics company, closed a $126 mill...

Friday 15th February 2019

Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device co...

Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antib...

$MRKR Announces Change in Corporate Headquarters and Access to New Laboratory Facility …

$MRKR Announces Change in Corporate Headquarters and Access to New Laboratory Facility …

Newly formed Arvelle licenses European rights to SK's anti-epileptic cenobamate

Newly formed Arvelle Therapeutics GMBH licensed exclusive European development and commercialization rights to SK Biopharmace...

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

GEN Webinar, Tuesday, March 12 -- Better by Design: Single-Cell Characterization for Enhanced Cell Therapeutics. Register now at:

GEN Webinar, Tuesday, March 12 -- Better by Design: Single-Cell Characterization for Enhanced Cell Therapeutics. Register now at:

Hoth Therapeutics Announces Pricing of Initial Public Offering and Trading on the Nasdaq

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. As quoted in the press release:  All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option … Continued The post Hoth Therapeutics Announces ...

Five Prime Therapeutics (FPRX) Presents At Guggenheim Healthcare Talks Idea Forum - Slideshow

Quick Search


News Quicklinks